Results 201 to 210 of about 1,358,589 (334)

The role of central noradrenergic systems in morphine tolerance development

, 2010
Pamela Susan Klonoff
openalex   +1 more source

The Case of a 28‐Year‐Old Woman With Medically Refractory Focal Epilepsy

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT We present the case of a 28‐year‐old right‐handed woman with medically refractory focal epilepsy. Her seizure semiology and electroencephalography (EEG) indicated a seizure onset zone in the right central‐parietal area. However, both MRI and PET scans were unremarkable, showing no focal lesions or areas of altered metabolism.
Rishi Sharma, Ilo Leppik, Thomas Henry, Thaddeus Walczak, Sima Patel, Robert McGovern   +5 more
wiley   +1 more source

Intrathymic Regulation of Dendritic Cell Subsets and Their Contributions to Central Tolerance. [PDF]

Immunol Rev
Calindi A, Ehrlich LIR.
europepmc   +1 more source

Olink Proteomics Analysis Reveals Heterogeneous Responses to FcRn Blockade in Anti‐AChR Antibody‐Positive Myasthenia Gravis: FGF‐19 as a Novel Biomarker

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective This study aimed to systematically observe the clinical manifestations, immune cell subsets, and dynamic changes in serological indicators in patients with myasthenia gravis (MG) before and after efgartigimod (EFG) treatment. Methods We analyzed the baseline data, laboratory parameters, and lymphocyte subset proportions in MG ...
Tiancheng Luo, Deyou Peng, Zhouao Zhang, Mingjin Yang, Xinyan Guo, Tianyu Ma, Xiaoyu Huang, Mingming Xu, Linlin Fu, Yong Zhang   +9 more
wiley   +1 more source

Will Memantine Exacerbate Seizures in People With Epilepsy? A Prospective Cohort Study

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To evaluate whether add‐on memantine would exacerbate seizures in people with epilepsy. Methods This was a prospective cohort study. People with epilepsy diagnosed with cognitive impairment were consecutively invited. Those who agreed were followed up for at least 24 weeks.
Peiyu Wang, Lu Lu, Hui Gao, Qi Zhang, Jing Xiao, Josemir W. Sander, Weixi Xiong, Dong Zhou   +7 more
wiley   +1 more source

Permissive central tolerance plus defective peripheral checkpoints license pathogenic memory B cells in CASPR2-antibody encephalitis. [PDF]

Sci Adv
Sun B, Fernandes D, Soltys J, Kienzler AK, Paneva S, Harrison R, Ramanathan S, Harrison AL, Makuch M, Fichtner ML, Donat RF, Akdeniz D, Bayuangga H, Im MG, Williams R, Vasconcelos A, Thomsen S, Fower A, Sun R, Fox H, Mgbachi V, Davies A, Tseng M, Handel A, Kelly M, Zhao M, Bancroft J, Bashford-Rogers R, Pluvinage JV, Dandekar R, Alvarenga BD, Dustin LB, Rinaldi S, Owens R, Anthony D, Bennett DL, Waters P, Davis SJ, Wilson MR, O'Connor KC, Carvalho AL, Irani SR.   +41 more
europepmc   +1 more source

Central nervous system tolerance to boron neutron capture therapy with p-boronophenylalanine [PDF]

, 1997
GM Morris, JA Coderre, P. L. Micca, C. D. Fisher, Jacek Capala, J. W. Hopewell   +5 more
openalex   +1 more source

Daratumumab Treatment for Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP): A Case Report

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is an immune‐mediated neuropathy featuring progressive weakness, sensory deficits, and areflexia. While corticosteroids, intravenous immunoglobulin, and plasmapheresis are effective first‐line immunotherapies, a subset of patients remains treatment‐refractory.
Xueyu Zhang, Jianli Zhao, Xue Zhao, Xiaowei Hu, Zichun Xiao, Jie Wu, Xiaowen Li, Jing Xu, Yu‐Jing Li   +8 more
wiley   +1 more source

Influence of molsidomine (Sidnofarma) on indices of central hemodynamics and tolerance disorders to physical activity in patients with stage II arterial hypertension

, 2018
М. М. Селюк, М. М. Козачок, І. М. Льовкін, В. В. Бесага, О. Г. Лівінська, М. А. Пономаренко, Л. М. Дударь   +6 more
openalex   +1 more source

In‐Depth Profiling Highlights the Effect of Efgartigimod on Peripheral Innate and Adaptive Immune Cells in Myasthenia Gravis

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Background Myasthenia gravis (MG) is an autoimmune disorder characterized by antibody‐mediated complement activation. Efgartigimod, a neonatal Fc receptor (FcRn) antagonist, is approved for treating generalized MG (gMG). However, its modulatory effects on upstream innate and adaptive immune cells remain largely unexplored.
Lei Jin, Liu Dong, Ying Wang, Dingxian He, Chong Yan, Jianying Xi, Haoqin Jiang, Yu Shi, Ming Guan, Chongbo Zhao, Jie Song, Sushan Luo   +11 more
wiley   +1 more source